Tobacco Dependence Clinical Trial
Official title:
Measuring Neuroadaptations in Response to Very Low Nicotine Content Cigarettes
Verified date | November 2023 |
Source | Milton S. Hershey Medical Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The overall goal of this study is to determine if switching to very low nicotine content cigarettes changes the function of brain circuitry involved in incentive salience and executive control among dependent smokers.
Status | Active, not recruiting |
Enrollment | 39 |
Est. completion date | January 2024 |
Est. primary completion date | June 23, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 21 Years to 60 Years |
Eligibility | Inclusion Criteria: - 21-60 years old - Smoke >5 cigarettes per day - >1 year of daily smoking - No quit attempt in prior month and not planning to quit smoking within next 3 months - Able to understand and consent to study procedures - High school or lower educational attainment or annual household income < $50,000 - Plan to live in local area next 3 months - Women not pregnant or nursing and taking steps to avoid pregnancy - Able to read and write in English - Access to computer with internet service that allows for Zoom Exclusion Criteria: - Use of non-cigarette tobacco products in the past 7 days - Use of illicit substances more than once a week in the past 3 months (excluding marijuana) - Current alcohol abuse impairing participation - MRI safety contraindications (e.g., metal implants, claustrophobia) - Unstable or significant medical conditions (e.g., COPD, coronary heart disease) - Major neurological conditions or brain trauma - Major surgeries planned in next 3 months - Use of smoking cessation medication in prior month (e.g., varenicline, patch) - Uncontrolled serious mental illness, suicidality, or inpatient psychiatric hospitalization in the past 6 months - Unwillingness to provide urine samples - Unwilling to smoke study assigned cigarettes for the remainder of the trial - Plans to move or take extended travel out of the area in the next 3 months - Any other condition or situation that would, in the investigator's opinion, make it unlikely that the participant could comply with the study protocol - Self-reported color blindness - Left-handedness - Smell dysfunction as determined via standardized assessment |
Country | Name | City | State |
---|---|---|---|
United States | Penn State Health | Hershey | Pennsylvania |
Lead Sponsor | Collaborator |
---|---|
Milton S. Hershey Medical Center | National Institutes of Health (NIH) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Changes in blood oxygen level dependent (BOLD) activity collected by fMRI | Effect of nicotine content on changes in task-related functional brain activation over 6-weeks | Changes in BOLD from baseline to the 6-week visit. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01928719 -
Reduced Nicotine Content Cigarettes in Smokers of Lower Socioeconomic Status
|
N/A | |
Completed |
NCT01995123 -
Behavioral Activation for Smoking Cessation in PTSD
|
N/A | |
Not yet recruiting |
NCT03249428 -
E-Cigarette Inner City RCT
|
N/A | |
Recruiting |
NCT02564289 -
Cardiovascular Effects of Chronic Snus Use
|
N/A | |
Completed |
NCT01928758 -
Reduced Nicotine Cigarettes in Smokers With Mood and Anxiety Disorders
|
N/A | |
Withdrawn |
NCT01847300 -
cSBI-M for Young Military Personnel
|
N/A | |
Completed |
NCT01570595 -
Positively Smoke Free on the Web (PSFW) for Smokers Living With HIV
|
Phase 1/Phase 2 | |
Completed |
NCT01428310 -
Study to Evaluate the Safety and Efficacy of Dietary Supplement Anatabloc in Reducing Daily Smokers' Urge to Smoke
|
Phase 1 | |
Recruiting |
NCT00977249 -
Varenicline for Long-term Nicotine Replacement Therapy (NRT) Users
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT00968513 -
Evaluation of Tobacco Treatment Strategies for Inpatient Psychiatry
|
Phase 3 | |
Completed |
NCT01113424 -
Bioequivalence Between Nicotine Replacement Products and Nicorette® Gum
|
N/A | |
Completed |
NCT00747643 -
Varenicline Effects on Cue Reactivity and Smoking Reward/Reinforcement
|
N/A | |
Completed |
NCT00722124 -
S-Adenosyl-L-Methionine (SAMe) for Smoking Abstinence
|
Phase 2/Phase 3 | |
Completed |
NCT01238627 -
Bioequivalence Between Two Oral Nicotine Sublingual Tablets, 2 mg and 4 mg
|
N/A | |
Completed |
NCT01228617 -
Single-dose Pharmacokinetics of Oral Nicotine Replacement Products
|
N/A | |
Completed |
NCT00296647 -
Smoking Cessation Intervention: Effectiveness in Primary Care
|
Phase 4 | |
Completed |
NCT00394420 -
Emergency Department Telephone Quitline
|
N/A | |
Recruiting |
NCT05487807 -
Adapting and Evaluating a Tobacco Use Cessation Program for People Living With HIV in Uganda and Zambia
|
Phase 1 | |
Completed |
NCT03553992 -
An Extended Facebook Intervention for Young Sexual and Gender Minority Smokers
|
N/A | |
Withdrawn |
NCT05440721 -
Clinical Trial of an Innovative Digital Therapeutic for Smoking Cessation With Biochemical Verification
|
N/A |